Hikma Pharmaceuticals has named Surendera Tyagi, Ph.D., as its CSO and global head of R&D. Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when its generic drug ...

Hikma has already cut 200 jobs since picking up generics business Roxane Labs from Boehringer Ingelheim, but more layoffs are coming. As CFO Khalid Nabilsi told Reuters, another 200 positions are ...